Premium
Comparative Safety of Bone Remodeling Agents with a Focus on Osteoporosis Therapies
Author(s) -
Kleerekoper Michael,
Schein Jeffrey R.
Publication year - 2001
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/00912700122010050
Subject(s) - osteoporosis , medicine , raloxifene , bone remodeling , calcitonin , adverse effect , context (archaeology) , intensive care medicine , concomitant , hormone replacement therapy (female to male) , teriparatide , calcitriol , vitamin d and neurology , pharmacology , bone mineral , paleontology , cancer , estrogen receptor , testosterone (patch) , breast cancer , biology
This article reviews the different treatments currently available for osteoporosis and examines the benefits and adverse events that are associated with each. While emphasizing safety considerations, this review summarizes the following treatments for osteoporosis: calcium supplements, fluoride, hormone replacement therapy, raloxifene, bisphosphonates, salmon calcitonin, and calcitriol. Before prescribing any of these agents, the clinician should review the risk/benefit profile of each drug in the context of the individual patient's history, concomitant diseases, concurrent medications, and general physical condition.